.Attribute Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of patients along with HER2+ innovative bosom cancer cells and active or dependable human brain metastases revealed constant intracranial activity and also systemic efficacy of T-DXd.